A Randomized, Parallel, Double-Blind, Placebo-Controlled, Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Background of Methotrexate.

Trial Profile

A Randomized, Parallel, Double-Blind, Placebo-Controlled, Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Background of Methotrexate.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs TRU 015 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jun 2013 Results for part A presented at the 14th Annual Congress of the European League Against Rheumatism.
    • 14 Jun 2010 Primary endpoint 'American College of Rheumatology 50% response criteria' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top